News coverage about Zymeworks (NYSE:ZYME) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zymeworks earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave news stories about the company an impact score of 44.9478362945497 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Zymeworks (NYSE:ZYME) traded up $0.15 during trading hours on Friday, hitting $8.73. The stock had a trading volume of 11,928 shares, compared to its average volume of 40,036. Zymeworks has a 1-year low of $6.25 and a 1-year high of $14.25.

ZYME has been the subject of a number of research reports. Zacks Investment Research upgraded Zymeworks from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a report on Tuesday, November 14th. Barclays reiterated an “underweight” rating and set a $8.00 target price on shares of Zymeworks in a report on Thursday, September 7th. Scotiabank cut Zymeworks from an “overweight” rating to an “underweight” rating in a report on Thursday, September 7th. Finally, Cormark reiterated a “buy” rating on shares of Zymeworks in a report on Saturday, September 30th. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. Zymeworks presently has an average rating of “Hold” and a consensus price target of $14.35.

ILLEGAL ACTIVITY NOTICE: “Zymeworks (ZYME) Given News Impact Rating of 0.25” was published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/zymeworks-zyme-given-news-impact-rating-of-0-25/1754271.html.

Zymeworks Company Profile

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.

Receive News & Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.